1. Long-Term Outcome of Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma 
John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J. Nevill, Janet Nitta, Aulan Le, Donna L. Forrest, Donna E. Hogge, Julye C. Lavoie, Stephen H. Nantel, Cynthia L. Toze, Clayton A. Smith, Micheal J. Barnett, Kevín W. Song 
Biology of Blood and Marrow Transplantation 
Volume 13, Issue 8, Pages (August 2007)
DOI: /j.bbmt
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Kaplan-Meier estimate of overall survival for patients who underwent AlloSCT (+) and ASCT (▵) (P = .94).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Kaplan-Meier estimate of event-free survival for patients who underwent AlloSCT (+) and ASCT (▵) (P = .64).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Cumulative incidence of treatment related mortality: mortality at 1 year was higher in patients who underwent AlloSCT compared to ASCT, but the difference was not significant (22% versus 14%; P = .21).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Cumulative incidence of relapse: relapse at 10 years was higher in patients who underwent ASCT compared to AlloSCT, but the difference was not significant (41% versus 60%; P = .10).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions